1. Home
  2. MLYS vs CMRE Comparison

MLYS vs CMRE Comparison

Compare MLYS & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.41

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Logo Costamare Inc. $0.0001 par value

CMRE

Costamare Inc. $0.0001 par value

N/A

Current Price

$12.75

Market Cap

1.9B

ML Signal

N/A

Company Overview

Basic Information
Metric
MLYS
CMRE
Founded
2019
1974
Country
United States
Monaco
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
MLYS
CMRE
Price
$15.41
$12.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
2
Target Price
★ $45.22
$20.00
AVG Volume (30 Days)
★ 1.8M
440.4K
Earning Date
11-04-2026
10-28-2026
Dividend Yield
N/A
★ 3.91%
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$5.55
Revenue Growth
N/A
N/A
52 Week Low
$15.33
$13.05
52 Week High
$47.65
$18.06

Technical Indicators

Market Signals
Indicator
MLYS
CMRE
Relative Strength Index (RSI) 28.91 29.12
Support Level N/A N/A
Resistance Level $31.19 $15.69
Average True Range (ATR) 1.42 0.52
MACD -0.40 -0.14
Stochastic Oscillator 6.21 2.84

Price Performance

Historical Comparison
MLYS
CMRE

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: